ADE, I HARDLY KNEW YE
GINA AND ME
MIDAS TOUCH
COPD POTPOURRI
I KNOW HOW TO USE MY INHALER
200
The incidence of this ADE is lowered after rinsing one's mouth after using an ICS inhaler
Oropharnygeal candidasis (thrush)
200
The only FDA-approved LAMA for asthma is available as a soft-mist inhaler
Spiriva Respimat
200
GOLD 1 classification indicates an FEV1 >/= ____ than predicted
80%
200
A narrow therapeutic index drug no longer recommended as part of routine chronic COPD management
Theophylline (methylxanthines)
200
This is a process performed prior to initial use or after extended disuse of an MDI
Priming
400
Levalbuterol is purported to less frequently cause this ADE compared to racemic albuterol
Tachycardia
400
One of the guideline-recommended (S)MART inhaler combinations
Budesonide/formoterol (Symbicort, Breyna)
Mometasone/formoterol (Dulera)
400
In addition to the mMRC scale, this feline scale assesses symptom severity with COPD
CAT
400
Triple therapy inhalers include these three classes of medications
ICS + LABA + LAMA
400
Decreased inspiratory flow with disease progression may make this inhaler type potentially more useful and easy to use for a patient
Soft mist inhaler (e.g., Respimat)
600
These two biologic treatments carry a BBW for anaphylaxis (name 1)
Omalizumab (Xolair) or rezlizumab (Cinqair)
600
An asthma severity classification for adults well controlled with low-intensity treatment (low-dose ICS-formoterol)
Mild asthma
600
(DAILY DOUBLE) An Andean native or an inhaler class indicated for all severities of COPD
LAMA
600
Once daily or three times weekly use of this macrolide for 1 yr can reduce COPD exacerbation rates compared to usual management
Azithromycin (Zithromax)
600
A counseling point for a DPI like Seebri Neohaler (glycopyrrolate)
1. Do not block air inlet
2. Breath in deep and fast
3. Avoid keeping in moist or wet environment
800
This drug received an FDA boxed warning for severe neuropsychiatric events in 2020 despite and advisory panel finding no increased risk
Montelukast (Singulair)
800
Asthma severity classification for patients uncontrolled despite optimized on high-dose ICS-LABA
Severe asthma
800
Patients with at least 1 mod/severe exacerbation in the last year are considered this GOLD group
Group E
800
Very severe COPD patients with chronic bronchitis can benefit from this oral PDE4 inhibitor
Roflumilast (Daliresp)
800
Valved holding chamber (spacer)
1000
Sudden withdrawal of this medication class, if given at a high dose for over 2 weeks, may lead to cardiovascular collapse and shock
Systemic/oral corticosteriods
1000
This add-on biologic therapy for severe asthma targets immunoglobulin E
Omalizumab (Xolair) or omalizumab-igec
1000
Exacerbation with blood eosinophils >300 cells/mL is an indication to start this type of therapy
Inhaled corticosteroids (ICS)
1000
Frequent pneumonia hospitalizations are a reason to stop this particular component of inhaler therapy for COPD
Inhaled corticosteroids (ICS)
1000
Ellipta device